VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  05/16 04:00:00 pm EDT
0.3907 USD   -1.86%
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue $178,000
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics Completes Phase 1b Data for FMX114 for Atopic Dermatitis

01/19/2022 | 08:51am EDT


ę MT Newswires 2022
All news about VYNE THERAPEUTICS INC.
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Revenue $178,000
MT
05/12VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
CI
05/12VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Up..
AQ
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/10VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
AQ
05/06VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium o..
AQ
04/08SECTOR UPDATE : Health Care Stocks Edge Upward Premarket Friday
MT
04/07VYNE Therapeutics Reports 'Positive' Efficacy Results From Phase 1b Portion of Atopic D..
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,67x
Yield 2022 -
Capitalization 22,6 M 22,6 M -
Capi. / Sales 2022 52,1x
Capi. / Sales 2023 5,38x
Nbr of Employees 28
Free-Float 91,0%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,39 $
Average target price 5,80 $
Spread / Average Target 1 385%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-61.70%23
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807